clinical trial · NCT06799741
A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection
DENV-3 Controlled Human Infection ModelAV-1 100 mgAV-1 300 mgAV-1 900 mgPlacebo
brief summary
The goal of this clinical trial is to determine the prophylactic and therapeutic effect of AV-1 in healthy adults using a DENV-3 controlled human infection model (CHIM)
started
Jan 7, 2025
primary completion
Mar 11, 2026
completion
Mar 11, 2026
last updated
Mar 31, 2026
official title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Compare the Safety and Efficacy of 3 Dose Levels of AV-1 in Healthy Adults Challenged With a Controlled Human Infection Strain of DENV-3
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol